» Articles » PMID: 27114540

Relationships Among CFTR Expression, HCO3- Secretion, and Host Defense May Inform Gene- and Cell-based Cystic Fibrosis Therapies

Overview
Specialty Science
Date 2016 Apr 27
PMID 27114540
Citations 49
Authors
Affiliations
Soon will be listed here.
Abstract

Cystic fibrosis (CF) is caused by mutations in the gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR) anion channel. Airway disease is the major source of morbidity and mortality. Successful implementation of gene- and cell-based therapies for CF airway disease requires knowledge of relationships among percentages of targeted cells, levels of CFTR expression, correction of electrolyte transport, and rescue of host defense defects. Previous studies suggested that, when ∼10-50% of airway epithelial cells expressed CFTR, they generated nearly wild-type levels of Cl(-) secretion; overexpressing CFTR offered no advantage compared with endogenous expression levels. However, recent discoveries focused attention on CFTR-mediated HCO3 (-) secretion and airway surface liquid (ASL) pH as critical for host defense and CF pathogenesis. Therefore, we generated porcine airway epithelia with varying ratios of CF and wild-type cells. Epithelia with a 50:50 mix secreted HCO3 (-) at half the rate of wild-type epithelia. Likewise, heterozygous epithelia (CFTR(+/-) or CFTR(+/∆F508)) expressed CFTR and secreted HCO3 (-) at ∼50% of wild-type values. ASL pH, antimicrobial activity, and viscosity showed similar relationships to the amount of CFTR. Overexpressing CFTR increased HCO3 (-) secretion to rates greater than wild type, but ASL pH did not exceed wild-type values. Thus, in contrast to Cl(-) secretion, the amount of CFTR is rate-limiting for HCO3 (-) secretion and for correcting host defense abnormalities. In addition, overexpressing CFTR might produce a greater benefit than expressing CFTR at wild-type levels when targeting small fractions of cells. These findings may also explain the risk of airway disease in CF carriers.

Citing Articles

Factor 3 regulates airway engraftment by human bronchial basal cells.

Reynolds S, Hill C, Alsudayri A, Stack J, Shontz K, Carraro G Stem Cells Transl Med. 2024; 14(1).

PMID: 39485996 PMC: 11825694. DOI: 10.1093/stcltm/szae084.


DNA-PKcs inhibition improves sequential gene insertion of the full-length cDNA in airway stem cells.

Stack J, Rayner R, Nouri R, Suarez C, Kim S, Kanke K Mol Ther Nucleic Acids. 2024; 35(4):102339.

PMID: 39398224 PMC: 11470261. DOI: 10.1016/j.omtn.2024.102339.


Amphiphilic shuttle peptide delivers base editor ribonucleoprotein to correct the CFTR R553X mutation in well-differentiated airway epithelial cells.

Kulhankova K, Cheng A, Traore S, Auger M, Pelletier M, Hervault M Nucleic Acids Res. 2024; 52(19):11911-11925.

PMID: 39315713 PMC: 11514481. DOI: 10.1093/nar/gkae819.


DNA-PKcs Inhibition Improves Sequential Gene Insertion of the Full-Length cDNA in Airway Stem Cells.

Stack J, Rayner R, Nouri R, Suarez C, Kim S, Kanke K bioRxiv. 2024; .

PMID: 39185207 PMC: 11343149. DOI: 10.1101/2024.08.12.607571.


Systematic optimization of prime editing for the efficient functional correction of CFTR F508del in human airway epithelial cells.

Sousa A, Hemez C, Lei L, Traore S, Kulhankova K, Newby G Nat Biomed Eng. 2024; 9(1):7-21.

PMID: 38987629 PMC: 11754097. DOI: 10.1038/s41551-024-01233-3.


References
1.
Cutting G . Cystic fibrosis genetics: from molecular understanding to clinical application. Nat Rev Genet. 2014; 16(1):45-56. PMC: 4364438. DOI: 10.1038/nrg3849. View

2.
Mohammad-Panah R, Demolombe S, Riochet D, Leblais V, Loussouarn G, Pollard H . Hyperexpression of recombinant CFTR in heterologous cells alters its physiological properties. Am J Physiol. 1998; 274(2):C310-8. DOI: 10.1152/ajpcell.1998.274.2.C310. View

3.
Pignatti P, Bombieri C, MARIGO C, Benetazzo M, Luisetti M . Increased incidence of cystic fibrosis gene mutations in adults with disseminated bronchiectasis. Hum Mol Genet. 1995; 4(4):635-9. DOI: 10.1093/hmg/4.4.635. View

4.
Zhang L, Button B, Gabriel S, Burkett S, Yan Y, Skiadopoulos M . CFTR delivery to 25% of surface epithelial cells restores normal rates of mucus transport to human cystic fibrosis airway epithelium. PLoS Biol. 2009; 7(7):e1000155. PMC: 2705187. DOI: 10.1371/journal.pbio.1000155. View

5.
Dahl M, Tybjaerg-Hansen A, Lange P, Nordestgaard B . DeltaF508 heterozygosity in cystic fibrosis and susceptibility to asthma. Lancet. 1998; 351(9120):1911-3. DOI: 10.1016/s0140-6736(97)11419-2. View